Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: Results from a randomized, controlled phase II study in patients with breast cancer and bone metastases

Community Oncology

Volumn 7, Issue 2, 2010, Pages 85-89

  Campbell Baird, Cynthia ^a   Lipton, Allan ^a   Sarkeshik, Makan ^b   Ma, Haijun ^b   Jun, Susie ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB;

ADULT; ADVANCED CANCER; ARTHRALGIA; ARTICLE; ASTHENIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

EID: 77649222170     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70560-5     Document Type: Article

References (25)

1. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
2. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-2037.
3. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-695.
4. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736-1740.
5. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-331.
6. Cameron D, Fallon M, Diel I. Ibandronate: its role in metastatic breast cancer. Oncologist 2006;11(suppl 1):27-33.
7. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(suppl 4):28-37.
8. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
9. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
10. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
11. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-696.
12. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14:6690-6696.
13. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437.
14. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptidebound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856.
15. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007;7(suppl 1):S14-S20.
16. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
17. Novartis Pharmaceuticals Corporation. Aredia (pamidronate disodium for injection) for intravenous infusion [package insert]. East Hanover, NJ; 2002.
18. Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid) concentrate for intravenous infusion [package insert]. East Hanover, NJ; 2005.
19. Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007;18:1165-1171.
20. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
21. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
22. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228.
23. Suarez T, Fizazi K, Rahim Y, et al. A randomized trial of denosumab (AMG 162) versus intravenous bisphosphonates in cancer patients with bone metastases on established IV BP and evidence of elevated bone resorption [abstract]. J Clin Oncol 2006;24:8562.
24. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007;1117:209-257.
25. Stolina M, Dwyer D, Ominsky MS, et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 2007;179:7497-7505.